Issuer Summary: China National Chemical Corporation / ChemChina

Report date: 2026-05-15
Issuer: China National Chemical Corporation Limited / ChemChina
Relevant bond issuer: CNAC (HK) Finbridge Company Limited
Ticker reference: HAOHUA
Bond structure reference: CNAC (HK) Finbridge offshore notes and perpetual securities guaranteed by China National Chemical Corporation Limited

1. Business Snapshot and Recent Developments

China National Chemical Corporation Limited (“ChemChina”) is a Chinese central government-owned chemical group with businesses spanning agrochemicals, chemical materials, tyres, chemical equipment, and legacy industrial chemical assets. In this report, HAOHUA refers to the foreign-currency bond ticker for instruments issued by CNAC (HK) Finbridge Company Limited with China National Chemical Corporation Limited as the reference credit; it does not refer to the listed subsidiary Haohua Chemical Science & Technology Corp. Ltd. (昊華科技) as the subject of analysis. For foreign-currency bonds referred to as HAOHUA, the legal entities bond investors should focus on directly are CNAC (HK) Finbridge Company Limited, the Hong Kong issuing SPV, and ChemChina, the guarantor. At the same time, since Sinochem Holdings Corporation Ltd. (“Sinochem Holdings”) was established in May 2021 through the restructuring of Sinochem Group and ChemChina, it is no longer sufficient to assess ChemChina solely as a standalone chemical company. Current credit analysis needs to distinguish among ChemChina-guaranteed bonds, ChemChina’s core status within Sinochem Holdings, and the support expectations associated with a Chinese central state-owned enterprise.

The issuer’s first defining feature is that its business scope is broader than that of a single chemical company, and that its business, debt, and control structures have become complex as a result of large overseas acquisitions. In the 2020 CNAC (HK) Finbridge Offering Circular, ChemChina’s businesses were grouped into five segments: New Chemical Materials and Speciality Chemicals, Agrochemicals, Petroleum Processing and Refining Products, Rubber Tyres, and Chemical Equipment. In particular, the 2017 acquisition of Syngenta connected ChemChina to the global agrochemicals and seeds business, but also materially increased the group’s debt burden. In addition, the group includes a number of overseas subsidiaries and associates that disclose their own financial and operating information in public markets, including Pirelli, ADAMA and Elkem. As a result, the group’s credit quality is affected not only by the cyclical profile of a Chinese domestic chemical company, but also by global agrochemicals, seeds, tyres, silicone and new materials, European regulation, foreign exchange, and overseas capital markets.

The second defining feature is the change in the parent-company structure after 2021. Sinochem Holdings’ official profile states that the company was established on 8 May 2021 through the joint restructuring of Sinochem Group and ChemChina, and that it is a central state-owned enterprise supervised by the State-owned Assets Supervision and Administration Commission of the State Council (SASAC). According to the same profile, Sinochem Holdings spans life sciences, material sciences, basic chemicals, environmental science, rubber and tyres, machinery and equipment, urban operations, industrial finance and other businesses, and as of end-2023 was a large-scale group with total assets of more than RMB1.6tn, annual revenue of more than RMB1tn, and more than 200,000 employees. ChemChina’s credit assessment therefore depends heavily not only on the historical financial metrics of the former ChemChina on a standalone basis, but also on Sinochem Holdings’ policy importance, business portfolio, willingness to support, and capacity to support.

The third defining feature is the distinction between bond structure and government support. CNAC (HK) Finbridge is ChemChina’s offshore financing SPV and has issued instruments including 2019 USD senior guaranteed bonds, and 2020 USD senior guaranteed bonds and subordinated perpetual securities. These instruments are guaranteed by ChemChina, but they are not directly guaranteed by the Chinese government. ChemChina’s position under Sinochem Holdings, a central SOE, ChemChina’s policy importance as a chemical group, and the support incorporated by rating agencies from the parent and the government are credit-supportive factors. However, this does not mean that the legal claim under each bond extends directly to the Chinese government.

The public information confirmed for this report as of 15 May 2026 is subject to important limitations. The 2020 Offering Circular includes ChemChina’s audited consolidated financial statements for 2017 to 2019 and unaudited data for 1H2020. By contrast, this workflow could not confirm ChemChina’s latest standalone audited consolidated financial statements after the Sinochem Holdings restructuring from public information. This report therefore does not make definitive statements on ChemChina’s latest standalone leverage or short-term debt. Instead, it separates issuer credit and unverified items by combining ChemChina’s historical financials, the scale and support capacity of parent company Sinochem Holdings, recent public performance data for major subsidiaries, and rating agencies’ support-inclusive views.

For bond investors, the company profile and structure can be framed as follows.

There are two simplifications to avoid when analysing this company. First, ChemChina cannot simply be treated as “safe because it is linked to the Chinese government”. Chemical and agrochemical cyclicality, elevated leverage following the Syngenta acquisition, overseas regulation, ESG and safety incidents, and individual bond terms are real risks. Second, it would also be inappropriate to look only at ChemChina’s historical high standalone leverage while ignoring support. Rating agencies have placed importance on ChemChina’s position within Sinochem Holdings after the restructuring and on the probability of support for a government-related issuer. The core purpose of this report is therefore to clarify the gap between standalone business risk and support-inclusive credit strength, and how that gap affects bondholders.

2. Industry Position and Franchise Strength

ChemChina’s business base is best assessed not through a simple scale comparison within the chemical industry, but through the industrial functions it performs across agricultural inputs, new materials, rubber and tyres, and chemical equipment. For the Chinese government, agricultural productivity, food security, localisation of chemical materials, industrial supply chains, and high-end manufacturing equipment are policy-relevant areas. Through the restructuring of state-owned chemical enterprises and overseas acquisitions, ChemChina has become a company with exposure to several of these policy domains.

However, policy importance does not automatically guarantee earnings stability. Syngenta Group’s full-year 2024 materials showed revenue of USD28.8bn and EBITDA of USD3.9bn, with both revenue and EBITDA declining from the previous year. ADAMA’s 2024 revenue also declined by 11% to USD4.141bn, while adjusted EBITDA increased by 15% to USD469mn, partly offsetting market weakness through cost and product-mix improvements. Pirelli has brand strength, technology, and a production base of 18 plants, but it is exposed to automotive demand, raw materials, foreign exchange, and constraints as a listed company with minority shareholders. In other words, ChemChina’s global business base increases asset value and the incentive to provide support, but it is not a source of fixed utility-like revenue and still carries cyclical risks in chemicals, agricultural inputs, and tyres.

Therefore, translating ChemChina’s franchise into credit strength requires more than describing it as a “global chemical group”. The proximity of agrochemicals, new materials, and tyres to China’s industrial policy and food security agenda strengthens support expectations. At the same time, whether cash from overseas subsidiaries reaches ChemChina-guaranteed bonds depends on ownership, dividends, subsidiary debt, minority shareholders, and local regulation. In this respect, ChemChina benefits from stronger support expectations than a standalone private chemical company, but unlike a policy financial institution, it is also an operating company with market, regulatory, and acquisition-related debt risks.

3. Segment Assessment

ChemChina’s segments should be assessed not only by whether they are large, but by whether they can preserve cash under stress, generate liquidity in a form that reaches bondholders, and provide a rationale for parent or government support. Due to public-information limitations, this report could not confirm ChemChina’s 2024 or 2025 standalone segment-level revenue and profit. Based on the business segmentation in the 2020 Offering Circular and recent disclosures by major public subsidiaries, the credit characteristics can be summarised as follows.

This table shows that business diversification is supportive, but not all segments stabilise in the same direction. Agrochemicals and tyres are linked to global demand but fluctuate with inventory and consumption cycles, while new materials are policy-relevant but exposed to capex and oversupply cycles. For ChemChina, segment diversification therefore needs to be assessed together with group debt, parent support, asset-disposal capacity, and liquidity management.

4. Financial Profile and Analysis

The first point to clarify in ChemChina’s financial analysis is the scope of the financial data obtained. The 2020 Offering Circular includes ChemChina’s audited consolidated financial statements for 2017, 2018 and 2019, as well as unaudited and unreviewed financial statements for 1H2020. By contrast, this report could not confirm ChemChina’s latest standalone audited consolidated financial statements after the 2021 Sinochem Holdings restructuring from public sources. Accordingly, the financial table below should not be read as “ChemChina’s precise current standalone financials”. It is used as base data confirming that ChemChina, after the Syngenta acquisition and around the period before and after the Sinochem Holdings restructuring, was highly leveraged.

From 2017 to 2019, ChemChina had a large revenue base but also a very heavy debt burden. In 2019, operating revenue was RMB454.3bn, EBITDA was RMB50.6bn, total debt was RMB453.4bn, and net debt was RMB375.3bn. On a simple calculation, total debt/EBITDA was about 9.0x and net debt/EBITDA was about 7.4x. On a standalone financial basis, this was not a level capable of supporting a high investment-grade profile through internal strength alone.

Note: Figures are based on the CNAC (HK) Finbridge Offering Circular 2020. Unit: RMB mn. EBITDA multiples are calculated by this report. These are not ChemChina’s latest standalone financials after the Sinochem Holdings restructuring from 2021 onward.

The most important point from this table is that the balance sheet was heavy after the Syngenta acquisition. EBITDA improved from 2018 to 2019, but total debt/EBITDA still remained around 9x, which is high for a normal chemical company. The credit quality of ChemChina-guaranteed bonds therefore needs to be explained not solely by standalone financial strength, but by considering parent and government-related support, asset value, and funding access together. Because the 1H2020 data are unaudited and unreviewed interim figures, they are not used for current financial assessment. The 2017-2019 table is also treated as evidence for separating ChemChina’s history of high standalone leverage from support-inclusive assessment.

Recent figures from major public subsidiaries supplement the business environment for the ChemChina group. Syngenta Group reported 2024 revenue of USD28.8bn and EBITDA of USD3.9bn, with revenue and EBITDA declining from the previous year. Inventory destocking in agricultural inputs, price declines, and weaker demand by region were likely factors. ADAMA’s 2024 revenue declined by 11% to USD4.141bn, while adjusted EBITDA increased by 15% to USD469mn, with cost and mix improvements partly offsetting market weakness. Pirelli showed net financial debt of EUR1.9258bn and parent-company shareholders’ equity of EUR5.7561bn at end-2024. These figures indicate that the major assets under ChemChina have their own business bases, but they do not substitute for the guarantor’s latest consolidated debt or liquidity.

Financial support factors include asset scale, the business value of major subsidiaries, integration into Sinochem Holdings, and funding access as a central SOE. S&P’s and Fitch’s support-inclusive ratings indicate that parent and government-related support compensate for ChemChina’s high standalone leverage. Constraints include insufficient transparency on latest standalone financials, the cyclicality of agrochemicals and chemical materials, and limitations on cash access from overseas subsidiaries. Investment analysis therefore needs to state explicitly the assumption that parent support is incorporated, while continuing to monitor parent-company EBITDA interest coverage, major subsidiary performance, short-term debt, and offshore bond maturities.

5. Structural Considerations for Bondholders

The most important structural issue for HAOHUA bonds is not to confuse the four layers: issuer, guarantor, parent, and government. CNAC (HK) Finbridge is a Hong Kong issuing SPV and is not an operating entity with business cash flow. ChemChina is the guarantor and the central credit claim entity for bond investors. Sinochem Holdings is the parent company after 2021 and is the group placed at the centre of rating agencies’ support assessments. The Chinese government and SASAC provide the background of ultimate ownership and supervision, but they are not guarantors of the individual bonds.

Based on the 2019 and 2020 SGX listings and Offering Circulars, CNAC (HK) Finbridge’s senior USD bonds were issued with a ChemChina guarantee. The senior bonds are linked to ChemChina’s credit. By contrast, the subordinated perpetual securities carry materially different risks from senior bonds because of distribution deferral, non-call, liquidation ranking, and distribution-resumption conditions.

The main HAOHUA-related foreign-currency securities confirmed from public information are as follows. Outstanding amount, call status, post-issuance NDRC/SAFE-related procedures, and whether guarantees were maintained, assumed, or supplemented after the restructuring need to be rechecked before investing in any specific bond.

The strength of the ChemChina guarantee is important, but how much support from Sinochem Holdings or the Chinese government should be priced in is a separate question. Rating agencies reflect parent and government-related support in their credit assessments, but within the scope of public materials confirmed by this report, Sinochem Holdings is not treated as an additional guarantor of each HAOHUA bond. How guaranteed obligations were maintained, assumed, or changed after the 2021 restructuring, and whether any additional guarantee, keepwell deed or support letter exists, need to be reconfirmed from the supplemental offering documents, announcements, and post-issuance filings for each bond.

Access to subsidiary assets also needs to be assessed carefully. Syngenta, Pirelli, ADAMA and others have valuable business franchises, but because they have their own debt, minority shareholders, listed-company regulation, local law and dividend constraints, holders of ChemChina-guaranteed bonds do not have a direct claim on the cash flows of those individual subsidiaries. Bond terms should be checked for guarantee scope, ranking, negative pledge, cross-default, change of control, tax gross-up, governing law, SAFE registration, NDRC registration or post-issuance filing, enforceability of cross-border guarantees, constraints on foreign-currency remittance from the PRC, and distribution deferral and call terms for perpetual securities.

In summary, HAOHUA senior bonds should be treated not as “Chinese government-guaranteed bonds”, but as “SPV bonds related to a central SOE group and guaranteed by ChemChina”. This distinction may appear only marginally in spreads during normal periods, but it becomes very important under stress. Recognising government support expectations while separating contractual claim, guarantor identity, debt ranking, and the discretionary nature of parent support is the starting point for investment analysis.

6. Capital Structure, Liquidity and Funding

ChemChina’s capital structure and liquidity cannot be fully reconstructed from public information alone. At the time of the 2020 Offering Circular, total debt at end-2019 was RMB453.4bn, cash and cash equivalents were RMB78.1bn, and net debt was RMB375.3bn. This was not a level at which the company could rapidly deleverage through standalone cash flow alone. Since 2021, following integration into Sinochem Holdings, funding and capital allocation are likely to be managed within the overall group. However, support expectations are not the same as actual liquidity. Investors need to check short-term debt, cash, unused bank lines, FX hedging, subsidiary dividends, domestic regulation, and offshore remittance constraints.

Funding support comes from bank access as a central SOE group, access to domestic capital markets, a track record of offshore bond issuance, major subsidiary assets, and parent support expectations. On the other hand, the historical high leverage can easily pressure interest coverage when earnings decline. If pesticide or chemical markets weaken and dividends from Syngenta, ADAMA, Pirelli and others become constrained, internal cash generation across the group would weaken. USD rates, the RMB exchange rate, US-China relations, and sanctions or export-control risks may also affect the required yield for foreign-currency bond investors.

Practical points for assessing capital structure and liquidity are as follows.

This report could not confirm ChemChina’s latest standalone cash, unused committed lines, short-term debt, or FX hedging details. Liquidity assessment should therefore be expressed as “strongly underpinned on the assumption of parent and central SOE support, but standalone figures are unconfirmed”. This is not a bearish conclusion; it is a necessary distinction between support-inclusive credit and transparency of standalone liquidity.

7. Rating Agency View

The key point in rating-agency views is that ChemChina is assessed not as a standalone highly leveraged chemical company, but as a core operating company under Sinochem Holdings. S&P Global Ratings upgraded ChemChina to A- in 2021, referred to ChemChina as A-/Stable in its 2025 China commodities outlook, and identified Sinochem Holdings’ EBITDA interest coverage falling below 2.0x as a downgrade trigger. In the public web search conducted for this report, no newer full detailed ChemChina-specific rating action beyond S&P’s 2021 action and 2025 materials was confirmed.

Fitch Ratings upgraded ChemChina to A in 2021, reflecting the establishment of Sinochem Holdings and support assessment under its government-related-issuer framework. Under Fitch’s framework, Sinochem Holdings is viewed as a government-related issuer anchored to the China sovereign, and ChemChina is assessed as an important subsidiary within that group. Subsequent Syngenta-related materials also refer to ChemChina at A/Stable, but because this report did not obtain the latest full Fitch action for ChemChina on a standalone basis, currency of the rating should remain a follow-up item.

For Moody’s, references to ChemChina at Baa2/Stable were confirmed in 2021 and 2022 Sinochem HK-related materials, but these were parent/related-issuer descriptions in the context of Sinochem HK’s rating, not the latest full action on ChemChina-guaranteed bonds themselves. In addition, public summaries from ResearchPool and Anrong’s weekly report in June 2024 state that Moody’s affirmed ChemChina’s Baa2 issuer rating and the ratings on CNAC (HK) Finbridge’s ChemChina-guaranteed senior unsecured bonds, and changed the outlook from Stable to Negative. A September 2025 public Cbonds page also summarises the rating as Baa2/Negative. However, because this report did not directly obtain Moody’s full official report, Moody’s is conservatively treated as “likely Baa2/Negative based on public secondary information”, and the official database or latest release should be checked before making a current investment decision.

There are three implications from the rating-agency views. First, ChemChina’s support-inclusive ratings are higher than its standalone financial profile. Second, downside risk is linked not only to ChemChina on a standalone basis, but also to Sinochem Holdings’ overall credit metrics, parent support assessment, and the support environment for the China sovereign and central SOEs. Third, a high rating does not automatically mean a government guarantee or strong individual bond terms.

The rating-agency views are broadly consistent with this report’s analysis. However, the guarantee, ranking, subordination, maturity, and live spread of individual bonds required for investment decisions cannot be replaced by ratings alone. The final step in an investment decision requires checking bond terms and market levels.

8. Credit Positioning

ChemChina’s relative positioning is easiest to understand across three axes: comparison with Chinese central SOEs and quasi-sovereigns; comparison with chemical and agrochemical companies; and comparison with other issuers and major subsidiaries within the Sinochem Holdings group. Across all three axes, ChemChina is best positioned as an issuer with “strong support expectations, but a cyclical standalone business and a history of high leverage”.

Compared with Chinese central SOEs, ChemChina has policy importance, but its profile differs from policy banks or immediately essential infrastructure such as power, telecoms, or railways. Agrochemicals, chemical materials, tyres and equipment are important to national industrial policy, and Sinochem Holdings as a whole plays a major role in China’s chemical and agricultural input supply chains. At the same time, this report has not confirmed any legal mechanism under which the state directly, immediately and unconditionally guarantees ChemChina’s bonds if ChemChina’s standalone debt becomes stressed. ChemChina is therefore strong on a support-inclusive basis, but it is not the same as a sovereign or policy bank.

Compared with chemical and agrochemical companies, ChemChina benefits from scale and policy support, but is constrained by transparency and financial burden. Global pesticide, seed and specialty-chemical companies have R&D, brands, sales networks and regulatory approvals, but they are exposed to economic, inventory and pricing cycles. ChemChina participates in this space through Syngenta and other assets, but the elevated debt burden after the 2017 acquisition remained a credit constraint. For a private chemical company, leverage at this level would likely be a major rating constraint. In ChemChina’s case, parent and government-related support compensate for that constraint.

Within the Sinochem Holdings group, ChemChina is a core legacy ChemChina asset platform and contains important businesses in agrochemicals, materials and tyres. However, the post-restructuring group also includes legacy Sinochem businesses in energy, chemicals, agriculture, real estate/urban operations, finance and other areas. ChemChina is not the only support target. Since the parent allocates capital across the entire group, ChemChina bonds may be likely to receive support, but the form, priority and timing of that support will depend on group-wide circumstances.

This report does not make a relative-value conclusion on whether the bonds are cheap or expensive, because live spreads, OAS, CDS, and same-maturity comparables were not confirmed. From a credit perspective alone, ChemChina senior bonds have a degree of support as China central SOE credits with government-support assumptions, but investors should require additional compensation for business, transparency, and structural risks relative to policy banks or more direct utility-like infrastructure SOEs. Perpetual securities are clearly riskier than senior bonds even within the same issuing group, and should not be treated on the same basis purely because of support expectations.

9. Key Credit Strengths and Constraints

ChemChina’s credit strengths include its role as a core chemical and agrochemical platform under Sinochem Holdings, its business scale and global exposure through Syngenta/Pirelli/ADAMA and others, access to the domestic financial system and capital markets as part of a central SOE group, and potential asset-restructuring capacity. Constraints include historical high leverage, insufficient transparency on latest standalone financials, cyclicality in agrochemicals, chemical materials and tyres, the gap between parent support and legal guarantees, and geopolitical, regulatory and ESG risks.

Overall, ChemChina is not a “chemical company with strong standalone financials”. It is an issuer with a history of high leverage whose credit quality is materially supplemented by central SOE parent support and strategic importance. Missing this distinction can lead either to excessive optimism or excessive pessimism.

10. Downside Scenarios and Monitoring Triggers

ChemChina’s downside is greatest when deterioration in the parent’s support capacity coincides with weaker business conditions. As S&P’s trigger based on Sinochem Holdings’ EBITDA interest coverage indicates, ChemChina’s credit quality is highly dependent on the financial flexibility of the parent group. At the same time, if agricultural chemical market conditions at Syngenta/ADAMA, earnings from chemical materials, basic chemicals and tyres, offshore bond markets, geopolitical risks, and structural differences across individual bonds all deteriorate simultaneously, bond valuations may move faster than standalone financials.

Conditions that would improve the credit view include stability in Sinochem Holdings’ financial metrics, debt reduction at ChemChina or major subsidiaries, bottoming of agrochemical market conditions for Syngenta/ADAMA, and improved transparency on ChemChina standalone financials, maturity schedule and liquidity. Conditions for deterioration include weaker parent metrics, lower support assessment, liquidity stress at major subsidiaries, difficulty refinancing offshore bonds, and simultaneous geopolitical or regulatory events.

11. Credit View and Monitoring Focus

The current credit level of ChemChina/HAOHUA senior bonds should, based on confirmed public S&P/Fitch materials, be viewed not as that of a standalone chemical company but as that of a core central SOE-related issuer under Sinochem Holdings, leaning toward the higher end of investment grade on a support-inclusive basis. However, the bonds should not be treated the same as directly government-guaranteed bonds or policy bank bonds. Based on S&P/Fitch, the credit direction appears relatively stable on a support-inclusive basis. By contrast, Moody’s public secondary information since 2024 indicates a Negative outlook, and the lack of confirmation of ChemChina standalone financials, Sinochem Holdings’ latest audited financials, and Moody’s full official report remains a constraint on the assessment. The probability of a sharp near-term decline in credit quality is not high as long as parent support is maintained, but if Sinochem Holdings’ support assessment weakens, parent interest coverage deteriorates, offshore bond markets close, and regulatory or geopolitical events occur simultaneously, bond valuations could deteriorate faster than standalone financials.

The main basis for this view is that ChemChina is a core chemical and agrochemical platform of Sinochem Holdings, and that Sinochem Holdings is a central SOE supervised by SASAC. Agrochemicals, materials, tyres and chemical equipment are linked to China’s industrial policy, food security, and material supply chains. For a normal private chemical company, historical total debt/EBITDA of around 9x would be a severe credit constraint. For ChemChina, parent and government-related support complements credit quality.

At the same time, weak standalone credit quality should not be ignored. ChemChina was highly leveraged at end-2019, and this report could not confirm the latest standalone financials after 2021. Syngenta’s lower 2024 revenue and EBITDA, ADAMA’s agrochemical market pressure, and cyclicality in chemicals and tyres demonstrate business volatility. A high support-inclusive rating does not mean ChemChina’s business cash flow is always stable.

For bond investors, the most important point is to separate support-inclusive credit from contractual claims. HAOHUA senior bonds are guaranteed by ChemChina and are stronger than a simple SPV bond. On the other hand, they are not directly guaranteed by Sinochem Holdings or the Chinese government. Issuer credit analysis should therefore emphasise parent support, while individual bond investment also needs to separately check guarantor identity, ranking, subordination, covenants, NDRC registration or post-issuance filing, SAFE registration, enforceability of cross-border guarantees, tax, governing law, and distribution deferral/call terms for perpetual securities.

For positioning, ChemChina senior bonds have a degree of defensiveness as support-inclusive China central SOE-related credits. At the same time, investors should require additional compensation for business cyclicality, transparency, structure and geopolitical risks relative to policy banks or more direct utility-like infrastructure SOEs. Because live spreads were not confirmed, this report does not conclude buy, sell, cheap or expensive. Investment decisions should test whether the spread pick-up versus same-maturity China sovereigns, policy banks, Sinochem-related bonds, and other central SOE chemical/resource companies sufficiently compensates for the business and structural risks described above.

Monitoring should focus on Sinochem Holdings’ latest consolidated financials and EBITDA interest coverage, the latest financials and maturity schedule on a ChemChina-guarantor basis, the performance and cash upstreaming of major subsidiaries including Syngenta/ADAMA/Pirelli, latest actions from S&P/Fitch/Moody’s, and the outstanding amounts, call status, terms and spreads of each HAOHUA bond. In this report, HAOHUA refers to the foreign-bond ticker and does not directly assess the equity credit profile of 昊華科技.

12. Short Summary & Conclusion

ChemChina is a large Chinese central SOE-related chemical group with businesses in agrochemicals, materials, tyres and chemical equipment. The HAOHUA foreign-currency bonds in this report should be analysed not as 昊華科技, but as bonds issued by CNAC (HK) Finbridge and guaranteed by ChemChina. Since 2021, parent and government-related support as a core subsidiary under Sinochem Holdings has materially supplemented credit quality. At the same time, ChemChina’s historical standalone leverage was heavy and transparency on latest standalone financials is limited. Senior bonds have a degree of defensiveness as support-inclusive China central SOE credits, but they are not directly guaranteed by the Chinese government or Sinochem Holdings. For individual bond investment, investors should separately check guarantor identity, ranking, subordination, maturities, parent-company metrics, the performance of major subsidiaries such as Syngenta, and live spreads.

13. Sources

Primary company and bond sources

• CNAC (HK) Finbridge Company Limited, Offering Circular dated 2020-09-15, including China National Chemical Corporation Limited guarantee and historical ChemChina financial statements: https://links.sgx.com/FileOpen/CNAC%20-%20Final%20Offering%20Circular.ashx?App=Prospectus&FileID=46499
• Singapore Exchange, CNAC (HK) Finbridge Company Limited US$900,000,000 3.875 per cent guaranteed bonds due 2029 listing confirmation, 2019-06-20: https://links.sgx.com/1.0.0/corporate-announcements/3A06LS7DTW77F7H2/d2c6576d348b65f79e42d01d35ddb6c544971e5ff4044532df120869f93c5d1d
• Sinochem Holdings official profile page, accessed 2026-05-15: https://www.sinochem.com/en/gywm/index.html
• Sinochem Holdings official site and report pages, accessed 2026-05-15: https://www.sinochem.com/
• Syngenta Group, Full Year 2024 Results, 2025-03-26: https://www.syngentagroup.com/newsroom/2025/fyr-2024
• Pirelli, Annual Report 2024: https://corporate.pirelli.com/corporate/en-ww/investors/financial-reports
• ADAMA, Q4 and Full Year 2024 Results page and related company releases, 2025-03-13: https://investors.adama.com/news-and-filings/quarterly-earnings-reports/Quarterly-Results-Q4-2024/default.aspx

Rating and supplementary sources

• S&P Global Ratings, ChemChina Ratings Raised To A- On Core Status Within Sinochem Holdings Group; Outlook Stable, 2021: https://www.spglobal.com/ratings/en/regulatory/article/-/view/sourceId/12176560
• S&P Global Ratings, 2025 Outlook -- China Commodities Watch, public table referencing ChemChina A-/Stable and Sinochem Holdings parent interest coverage trigger, 2025-01-06: https://www.spglobal.com/ratings/en/regulatory/article/250106-2025-outlook-china-commodities-watch-commodity-chemicals-face-a-tougher-road-back-than-agrochemicals-s13374191
• Fitch Ratings, Fitch Upgrades China National Chemical to A; Outlook Stable, 2021. Full current action not obtained; used as support-framework background.
• Fitch Ratings / MarketScreener, Fitch Affirms Syngenta Group at A; Outlook Stable, 2022-11-17, referencing ChemChina A/Stable and Sinochem Holdings support framework: https://www.marketscreener.com/quote/stock/SINOCHEM-INTERNATIONAL-CO-6497185/news/Fitch-Affirms-Syngenta-Group-at-A-Outlook-Stable-42339920/
• Moody's Ratings, Sinochem Hong Kong-related rating action materials referencing China National Chemical Corporation Limited Baa2 / Stable, 2021: https://hk.sinochem.com/Portals/196/Uploads/Files/2022/8-26/637971149082501834.pdf
• ResearchPool public summary, Moody's Ratings affirms China National Chemical Corporation Limited's Baa2 ratings and revises outlook to negative, 2024-06-21: https://app.researchpool.com/provider/moodys-investors-service/moodys-ratings-affirms-china-national-chemical-corporation-limiteds-ba-CFKUHoF9oS
• Anrong Credit Rating weekly report quoting Moody's 2024-06-20 ChemChina action and negative outlook: https://www.arrating.cn/uploads/allimg/20240701/3-240F1155T5420.pdf
• Cbonds public summary, Moody's affirms China National Chemical Corporation at Baa2; outlook negative, 2025-09-12: https://cbonds.com/news/3583625/
• Cbonds public bond pages for CNAC (HK) Finbridge / HAOHUA securities, used only for bond identifier cross-checks, not for live valuation.
• Goldstone Capital Group annual report references to CNAC (HK) Finbridge / China National Chemical Corporation bond holdings, used only as supplementary public cross-check.

14. Unverified / Pending

1. ChemChina standalone audited financial statements for 2024 or 2025 were not obtained in this workflow. The latest ChemChina financial table in this report uses 2017-2019 audited data from the 2020 Offering Circular and should not be treated as current standalone financials.
2. Sinochem Holdings' latest audited consolidated financial statements, EBITDA, interest expense, debt maturity table and explicit ChemChina support arrangements should be obtained before tightening the parent support analysis.
3. Latest S&P, Fitch and Moody's ChemChina-specific rating action reports should be checked from the agencies' own platforms before using precise current rating triggers in a trade recommendation. Moody's Baa2 / Negative is reflected here from public secondary summaries, not from the full official Moody's report.
4. Specific HAOHUA bond documentation should be rechecked before investing in any issue, including current outstanding amount, guarantee scope, ranking, negative pledge, cross default, tax gross-up, governing law, NDRC registration or post-issue filing, SAFE registration, cross-border guarantee enforceability, PRC remittance constraints, perpetual securities' distribution deferral and call terms.
5. Major subsidiary cash access should be confirmed before relying on Syngenta, ADAMA or Pirelli as support resources: ownership percentage, dividends, minority shareholder rights, subsidiary debt, local law and regulatory restrictions remain pending.
6. Current bond prices, spreads, OAS, CDS, and same-maturity peer comparisons were not available in this workspace and are not used to make a relative-value conclusion.